Depomed Announces Second Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
DepoMed Inc (DEPO) PT Lowered to $9 at Piper Jaffray
August 8, 2017 8:23 AM EDTPiper Jaffray lowered its price target on DepoMed Inc (NASDAQ: DEPO) to $9.00 (from $10.00) while maintaining a Neutral rating following Q2 results and another downward guide.
"Notably, DEPO cut its 2017 revenue and EBITDA guidance ranges once again, driven in part by continued headwinds... More
Depomed (DEPO) Misses Q2 EPS by 1c, Trims FY Guidance
August 7, 2017 4:03 PM EDTDepomed (NASDAQ: DEPO) reported Q2 EPS of $0.08, $0.01 worse than the analyst estimate of $0.09. Revenue for the quarter came in at $100 million versus the consensus estimate of $99.42 million.
GUIDANCE:
Depomed sees FY2017 revenue of $395-410 million, versus the consensus of $416.3... More
